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ABSTRACT
Objective To compare the effectiveness and risk profile of
newer methods for endoscopic ablation of the prostate
against the current standard of transurethral resection.
Design Systematic review and meta-analysis.
Data sources Electronic and paper records in subject area
up to March 2006.
Review methodsWe searched for randomised controlled
trials of endoscopic ablative interventions that included
transurethral resection of prostate as one of the treatment
arms. Two reviewers independently extracted data and
assessed quality. Meta-analyses of prespecified
outcomes were done using fixed and random effects
models and reported using relative risk or weightedmean
difference.
ResultsWe identified 45 randomised controlled trials
meeting the inclusion criteria and reporting on 3970
participants. The reportswereofmoderate to poor quality,
with small sample sizes. None of the newer technologies
resulted in significantly greater improvement in symptoms
than transurethral resection at 12 months, although a
trend suggested a better outcome with holmium laser
enucleation (random effects weighted mean difference
−0.82, 95% confidence interval 1.76 to 0.12) and worse
outcome with laser vaporisation (1.49, −0.40 to 3.39).
Improvements in secondarymeasures, suchas peakurine
flow rate, were consistent with change in symptoms.
Blood transfusion rates were higher for transurethral
resection than for the newer methods (4.8% v 0.7%) and
men undergoing laser vaporisation or diathermy
vaporisation were more likely to experience urinary
retention (6.7% v 2.3% and 3.6% v 1.1%). Hospital stay
was up to one day shorter for the newer technologies.
Conclusions Although men undergoing more modern
methods of removing benign prostatic enlargement have
similar outcomes to standard transurethral resection of
prostate along with fewer requirements for blood
transfusion and shorter hospital stay, the quality of
current evidence is poor. The lack of any clearly more
effective procedure suggests that transurethral resection
should remain the standard approach.
INTRODUCTION
Clinical benign enlargement of the prostate is a
syndrome comprising symptoms of the lower urinary
tract in conjunction with benign prostatic hypertrophy
and usually a reduced peak urinary flow rate. It is
highly prevalent among older men, affecting 30% of
those older than 60 and 40% of those older than 70.1
Although the precise relation between symptoms,
pathological evidence of hyperplasia, and bladder
outlet obstruction is debatable, removal of prostate
tissue in men with suspected clinical benign prostatic
enlargement generally results in substantial reduction
of symptoms, resolution of obstruction, and improved
wellbeing.
For many years transurethral resection of the
prostate has been the standard endoscopic technique
for ablation of benign prostate tissue, and improve-
ments in optics, diathermy, and anaesthesia have
reduced treatment relatedmorbidity to a relatively low
level.1 Despite this, transurethral resection requires
technical skill; causes physiological stress, affecting
recovery in somemen; carries some risks; anddoes not
satisfactorily improve symptoms in all men.2 This has
encouraged thedevelopmentof alternative endoscopic
proceduresusingother energy sources, suchas lasers to
ablate prostate tissue by resection or vaporisation.
Ideally, such procedures should have a satisfactory
evidence base showing advantage over transurethral
resection before generalised introduction. We carried
out a systematic review using data from randomised
controlled trials to determine whether these newer
procedures are better than transurethral resection of
the prostate for greater improvements in urinary
symptoms or a reduced risk of adverse events such as
the need for blood transfusion.
METHODS
To identify published and unpublished reports of
relevant randomised controlled trials we carried out
highly sensitive electronic searches of Medline (1966-
September, week 3, 2006), Embase (1980-2006, week
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Table 1 | Summary of baseline characteristics of included studies on alternative approaches to endoscopic ablation for benign enlargement of prostate.
Values aremeans unless stated otherwise
Study Comparator with transurethral resection of prostate No of participants
Age
(years) Symptom score*
Urine flow
(Qmaxml/s)
Residual
volume (ml)
Prostate
size (ml)
Gupta 2006w1 Holmium laser enucleation 50, 50 66, 66 23.4, 23.3 5.1, 4.5 112, 84 58, 60
Kuntz 2004w2 Holmium laser enucleation 100, 100 68, 69 22.1, 21.4 4.9, 5.9 238, 216 53, 50
Montorsi 2004w3 Holmium laser enucleation 52, 48 65, 64 21.6, 21.9 8.2, 7.8 4, 4 70, 56
Westenberg 2004w4 Holmium laser enucleation 61, 59 67, 67 21.9, 23.0 8.9, 9.1 88, 85 44, 45
Wilson 2006w5 Holmium laser enucleation 30, 30 71, 70 26.0, 23.7 8.4, 8.3 113, 126 78, 70
Bouchier-Hayes 2006w6 Laser vaporisation 38, 38 65, 66 NR, NR NR, NR NR, NR 42, 33
Carter 1999w7 Laser vaporisation 95, 96 68, 67 20.3, 19.8 9.0, 9.5 109, 135 42, 42
Keoghane 2000w8 Laser vaporisation 72, 79 69, 70 19.9, 19.4 11.8, 11.4 NR, NR 55, 52
Mottet 1999w9 Laser vaporisation 17, 13 64, 67 21.7, 23.7 8.8, 7.7 NR, NR 37, 34
Sengor 1996w10 Laser vaporisation 30, 30 61, 66 21.8, 22.1 8.7, 8.4 110, 155 NR, NR
Shingleton2002w11 Laser vaporisation 50, 50 68, 67 22, 21 NR, NR NR, NR 32, 30
Suvakovic 1996w12 Laser vaporisation 10, 10 63, 66 18.0, 18.8 12.2, 11.1 140, 162 24, 22
Tuhkanen 2001w13 Laser vaporisation 21, 25 67†, 67† 23†‡, 19†‡ 7.2, 8.5 138, 125 55, 55
Tuhkanen 2003w14 Laser vaporisation 26, 26 68†, 67† 18†‡, 18†‡ 8.3†, 8.6† 87†, 83† 30†, 28†
Van Melick 2003w15 Laser vaporisation 45, 50 67, 66 18.9, 16.8 12.0, 11.0 300, 350 37, 37
Zorn 1999w16 Laser vaporisation 21, 12 71, 69 24.0, 24.7 8.7, 9.0 NR, NR 30, 34
Helke 2001w17 Transurethral vaporesection 93, 92 69, 67 17.29, 18.29 10.8, 8.5 76, 102 49, 50
Kupeli 2001w18 Transurethral vaporesection 50, 50 61, 59 21.6, 19.4 9.2, 7.9 NR, NR 57, 58
Gupta 2006w1 Transurethral vaporesection 50, 50 68, 66 24.9, 23.3 4.6, 4.5 103, 84 63, 60
Liu 2006w19 Transurethral vaporesection 44, 32 66, 65 25.6, 26.8 6.9, 6.9 131, 142 58, 60
Talic 2000w20 Transurethral vaporesection 34, 34 71, 70 24.9, 20.1 7.5, 9.1 NR, NR 57, 52
De Sio 2006w21 Bipolar transurethral resection 35, 35 59, 61 24.2, 24.3 7.1, 6.3 80, 75 52, 47
Kim 2006w22 Bipolar transurethral resection 25, 25 68, 71 19.0, 18.6 6.5, 6.1 NR, NR 53, 52
Tefekli 2005w23 Bipolar transurethral resection 51, 50 69, 69 NR, NR NR, NR NR, NR 54, 50
Nuhog˘lu 2006w24 Bipolar transurethral resection 27, 30 65, 65 17.6, 17.3 6.9, 7.3 96, 88 47, 49
Seckiner 2006w25 Bipolar transurethral resection 24, 24 61, 64 24.1, 23.2 8.5, 8.3 88, 138 49, 41
Singh 2005w26 Bipolar transurethral resection 30, 30 69, 68 20.5, 21.6 5.8, 5.1 124, 136 NR, NR
Çetinkaya 1996w27 Transurethral vaporisation 23, 23 68, 62 NR, NR NR, NR NR, NR 48.4, 48.8
Ekengren 2000w28 Transurethral vaporisation 26, 28 70, 71 25†, 22† NR, NR NR, NR NR, NR
Erdag˘i 1999w29 Transurethral vaporisation 20, 20 66, 64 21.5, 20.6 4.6, 5.1 123, 68 37, 32
Fowler 2005w30 Transurethral vaporisation 115, 120 70, 70 20.7, 20.7 10.1, 10.5 181, 171 54, 51
Gallucci 1998w31 Transurethral vaporisation 70, 80 NR, NR 18.8, 18.2 7.3, 8.9 85, 65 37, 37
Gotoh 1999w32 Transurethral vaporisation 23, 28 70, 66 19.6, 18.9 7.3, 9.4 57, 42 57, 45
Hammadeh 2003w33 Transurethral vaporisation 52, 52 67, 70 26.5, 26.6 8.9, 8.6 131, 101 32, 27
Kaplan 1998w34 Transurethral vaporisation 32, 32 67, 73 NR, NR NR, NR NR, NR NR, NR
Kupeli 1998aw35 Transurethral vaporisation 30, 30 60, 62 21.6, 19.4 9.2, 7.9 NR, NR 52, 49
Kupeli 1998bw36 Transurethral vaporisation 30, 36 66, 62 13.7, 14.6 8.3, 8.8 NR, NR 42, 44
Nathan 1996w37 Transurethral vaporisation 20, 20 65, 69 21.9, 17.0 10.2, 7.2 132, 120 53, 53
Netto 1999w38 Transurethral vaporisation 40, 38 67, 65 19.6, 24.3 7.9, 6.8 73, 89 47, 45
Nuhog˘lu 2005w39 Transurethral vaporisation 37, 40 64, 65 17.6, 17.3 6.3, 5.9 88, 95 39, 39
Patel 1997w40 Transurethral vaporisation 6, 6 66, 67 23.3, 29.6 7.5, 10 NR, NR 65, 54
Shokeir 1997w41 Transurethral vaporisation 35, 35 68, 68 26.3, 25.1 7.8, 6.9 75, 77 45, 49
Wang 2002w42 Transurethral vaporisation 97, 109 71, 72 20, 20 7, 7 1231, 120 NR, NR
Van Melick 2003w15 Transurethral vaporisation 46, 50 64, 66 20.2, 16.8 11, 11 290, 350 35, 37
Fung 2005w43 Bipolar transurethral vaporesection 29, 31 72, 73 15.8, 19.4 NR, NR NR, NR NR, NR
Dunsmuir 2003w44 Bipolar transurethral vaporisation 30, 21 63, 60 24, 17 9.6, 10.4 112, 96 39, 42
Hon2006w45 Bipolar transurethral vaporisation 81, 79 66, 68 21, 21 12, 12 147, 182 38, 40
NR=not reported. Total number of trials is 45 with 47 relevant comparisons.
*International prostate symptom score or American Urological Association symptom index.
†Median.
‡Danish prostatic symptom score (Dan-PSSI-1).
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38), Medline In-Process (27 September 2006), Biosis
(1985-22 September 2006), Science Citation Index
(1981-23 September 2006), ISI Proceedings (1990-18
March2006),CochraneControlledTrialsRegister and
Cochrane Database of Systematic Reviews (Cochrane
Library, Issue 1, 2006), Database of Abstracts of
Reviews of Effectiveness (March 2006), Health Tech-
nology Assessments database (March 2006), National
Research Register (Issue 1, 2006), Clinical Trials
(March 2006), and Current Controlled Trials (March
2006). We also searched the proceedings of recent
conferences of the European Association of Urology,
AmericanUrological Association, andBritishAssocia-
tion of Urological Surgeons. We defined ablative
endoscopic treatments as those that resulted in
immediate removal of tissue, usually by resection or
vaporisation, and did not include procedures that
caused delayed tissue necrosis, such as microwave and
radiofrequency therapy. Searches were not restricted
by publication year or language and included con-
ference proceedings and abstracts. We scanned the
reference lists of all included studies to identify
additional potentially relevant studies. (Full details of
the search strategies are available from the authors.)
Two reviewers (TL, Angela Coutts, or Susan Wong)
independently screened the titles and abstracts of
identified papers and obtained full text copies of all
potentially relevant studies.
Study selection and study characteristics
We included randomised controlled trials if they
assessed endoscopic ablative interventions and
included transurethral resection as one of the treatment
arms.We excluded trials that reported onmenwithout
a clinical diagnosis of benign prostatic enlargement;
comparisons with conservative management; and
trials of interventions not involving tissue removal,
such as transurethral incision. Table 1 lists the
interventions considered (also see supplementary
table 1 on bmj.com).
The primary outcome measure was change in
symptom score at 12 months after surgery, measured
by the international prostate symptom score or the
American Urological Association symptom index—
these were considered equivalent and therefore we
combined the results from trials using these instru-
ments. The international prostate symptom score or
American Urological Association symptom question-
naire asks men to rate four voiding symptoms (poor
stream, intermittent flow, straining, incomplete empty-
ing) and three storage symptoms (frequency, nocturia,
urgency) on a scale from 0 (not present) to 5 (severe) to
give a total score ranging from 0 to 35, with severity of
symptoms defined as mild (0-7), moderate (8-19), or
severe (20-35).
Secondary outcomes were blood transfusion, urin-
ary incontinence, urinary retention, urinary tract
infection, loss of ejaculation, erectile dysfunction,
quality of life, peak urine flow rate, duration of
operation, length of hospital stay, and reoperation.
We considered all reports of prespecified complica-
tions regardlessof their timing.As separate reportingof
bladder neck stenosis and urethral stricture was
inconsistent we combined these complications.
Validity assessment and data abstraction
Two reviewers (TL, AC, or SW) independently
assessed the methodological quality of the full text
studiesusinganassessment tool drawingon the schema
suggested by the National Health Service Centre for
Reviews and Dissemination,3 Verhagen et al,4 Downs
and Black,5 and the generic appraisal tool for epide-
miology. Judgments on quality were based on the
qualitative assessment of the number and type of
criteria met by individual studies.
Holmium laser enucleation v TURP
  Gupta 2006w1
  Kuntz 2004w2
  Montorsi 2004w3
  Wilson 2006w5
  Westenberg 2004w4
Total (95% CI): -0.82 (-1.76 to 0.12)
P=0.09, I2=65.8%
Laser vaporisation v TURP
  Keoghane 2000w8
  Van Melick 2003w15
  Shingleton 2002w11
  Suvakovic 1996w12
Total (95% CI): 1.49 (-0.40 to 3.39)
P=0.12, I2=55.7%
Transurethral vaporesection v TURP
  Gupta 2006w1
  Helke 2001w17
Total (95% CI): -0.28 (-1.01 to 0.45)
P=0.45, I2=0%
Bipolar transurethral resection v TURP
  Nuhoglu 2006w24
  Seckiner 2006w25
Total (95% CI): 0.29 (-1.12 to 1.71)
P=0.69, I2=0%
Transurethral vaporisation v TURP
  Galluci 1998w31
  Gupta 2006w1
   Hammadeh 2003w33
  Kaplan 1998w34
  Van Melick 2003w15
   Shokeir 1997w41
Total (95% CI): -0.18 (-0.31 to 0.67)
P=0.48, I2=12.8%
50
89
48
25
43
255
52
37
40
9
138
50
79
129
24
23
47
70
50
51
30
34
25
260
-10 -5 0 5 10
Symptom score at 12 months
Favours
intervention
Favours
TURP
Random effects
Weighted mean
difference (95% CI)
No in
group
5.20 (1.20)
1.70 (1.80)
3.90 (3.60)
4.30 (3.50)
4.20 (6.00)
8.87 (6.51)
3.60 (3.40)
6.00 (6.00)
8.70 (4.90)
5.40 (1.97)
4.66 (4.30)
5.40 (3.70)
8.70 (4.10)
4.04 (4.26)
5.40 (1.97)
4.40 (3.80)
6.60 (2.40)
4.80 (4.90)
5.20 (1.40)
Intervention
Mean (SD)
50
86
52
27
41
256
60
41
33
10
144
50
73
123
26
21
47
80
50
51
31
41
25
278
No in
group
5.60 (2.26)
3.90 (3.90)
4.10 (2.30)
5.00 (4.68)
4.30 (4.10)
5.77 (5.40)
4.10 (4.80)
3.80 (4.10)
7.20 (6.10)
5.60 (2.26)
5.21 (5.10)
5.20 (3.20)
8.30 (2.90)
3.52 (3.04)
5.60 (2.26)
5.90 (5.20)
6.10 (1.90)
4.10 (4.80)
4.70 (1.50)
TURP
Mean (SD)
Fig 1 | Meta-analyses of symptom scores 12 months after endoscopic techniques for ablation of
benign enlargement of prostate. TURP=transurethral resection of prostate
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The two reviewers recorded details of methodology,
interventions, participants’ characteristics, and out-
comes on a data extraction form. Any differences that
could not be resolved through discussionwere decided
by an arbiter. For trials with multiple publications we
included only the most complete report for each
outcome.
Quantitative data synthesis
For meta-analysis we combined data on dichotomous
outcomes using the Mantel-Haenszel relative risk
method. For continuous outcomes we used the inverse
variance weighted mean difference method and 95%
confidence intervals. We intended to report results
using a fixed effects model throughout, but we had to
use a random effects model for symptom score and
peak urine flow rate because of statistical heterogene-
ity, explored by χ2 tests and I2 statistics. We used the
standard Cochrane software RevMan 4.2.8 for meta-
analyses.
RESULTS
The initial search generated 3794 reports, of which 621
were selected for full assessment (see supplementary
fig 1 on bmj.com). Eighty reports describing 45 trials
met the eligibility criteria (table 1).
The 45 randomised controlled trialsw1-w45 were
assessed as being of moderate or poor quality (see
supplementary table 2 on bmj.com). Only six studies
(13%) explicitly stated that an intention to treat analysis
was done and in three of these the analysis was
compromised by failure to include all the participants
in each arm at follow-up assessments.w8 w30 w45 The
eligible randomised controlled trials included 47
relevant comparisons involving 3970 participants.
Study setting and baseline characteristics of the
patients, such as severity of the disease, varied across
the included trials. Differences in outcome for bipolar
transurethral vaporisation and bipolar transurethral
vaporesection could not be assessed owing to lack of
data.
Quantitative data synthesis
Symptom scores—The results from studies reporting
changes in symptom score from baseline to
12 months showed significant heterogeneity, and
hence random effect meta-analyses were done (fig 1).
Larger mean changes were reported after holmium
laser enucleation in all five trials with suitable data
(weighted mean difference −0.82, 95% confidence
interval −1.76 to 0.12; P=0.09).w1-w5 In contrast, of four
trials on laser vaporisationw8 w11 w12 w15 threew8 w11 w12
favoured transurethral resection (1.49, −0.40 to 3.39;
P=0.12). No evidence was found of differences for
transurethral vaporesection, bipolar transurethral
resection, or transurethral vaporisation. The seven
trials with data that could not be included in the meta-
analysis were consistent with these findings (see
supplementary table 3 on bmj.com).
Peak urine flow rate—The results for peak urine flow
rate at 12 months were generally consistent with those
for symptom scores. Compared with transurethral
resection of the prostate higher rates were reported for
holmium laser enucleation (weighted mean difference
1.48 ml/s, 95% confidence interval 0.58 to 2.40;
P=0.002) and lower rates for laser vaporisation
(−2.02 ml/s, −4.75 to 0.81; P=0.15); overall, no
differences were found after the other procedures, but
heterogeneitywas present between the individual trials
(fig 2).
Quality of life—The quality of life of patients at
12 months after surgery was sparsely reported across
the different interventions (see supplementary table 3
onbmj.com).When reported, quality of lifewasmainly
rated using the international prostate symptom quality
of life question score from 0 (good) to 6 (poor). No
differences in improvements in quality of life scores
were detected, but confidence intervals were wide.
Blood transfusion—Meta-analyses showedevidenceof
a lower rate of blood transfusion after holmium laser
enucleation (relative risk 0.27, 95%confidence interval
0.07 to 0.95; P=0.04), laser vaporisation (0.14, 0.05 to
0.42; P=0.004), and transurethral vaporisation (0.18,
0.07 to 0.46; P<0.001) compared with transurethral
resection, whereas no significant difference was found
for transurethral vaporesection and bipolar transure-
thral resection (fig 3). Combining data for all newer
interventions showed an absolute risk reduction from
4.8% to 0.7%.
Urinary retention—The risk of postoperative urinary
retention requiring recatheterisation was higher after
laser vaporisation and transurethral vaporisation than
after transurethral resection (11.3% v 3.8%, relative risk
2.89,95%confidence interval1.53 to6.29; 8.9% v2.5%,
3.10, 1.53 to 6.29, respectively), whereas nodifferences
were seen with holmium laser enucleation and bipolar
transurethral resection (fig 3). Data on transurethral
vaporesection were insufficient for meta-analysis.
Strictures—The rate of strictures during follow-up
after holmium laser enucleation, transurethral
Table 2 | Effect on sexual function of alternative approaches to endoscopic ablation for benign
enlargement of prostate
Outcome No of trials Relative risk (95% CI) P value
Holmium laser enucleation:
Loss of ejaculation 2 1.14 (0.95 to 1.36) 0.15
Erectile dysfunction 1 NE NE
Laser vaporisation:
Loss of ejaculation 5 0.22 (0.13 to 0.39) <0.001
Erectile dysfunction 2 8.89 (1.29 to 61.37) 0.03
Transurethral vaporesection:
Loss of ejaculation 2 1.16 (0.85 to 1.58) 0.35
Erectile dysfunction 3 1.05 (0.58 to 1.81) 0.86
Bipolar tansurethral resection:
Loss of ejaculation 1 0.93 (0.68 to 1.27) 0.64
Erectile dysfunction 0 — —
Transurethral vaporisation:
Loss of ejaculation 6 0.78 (0.64 to 0.95) 0.01
Erectile dysfunction 8 1.02 (0.70 to 1.47) 0.93
NE=not estimable.
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vaporesection, bipolar transurethral resection, and
transurethral vaporisation was similar to that after
transurethral resection. Strictures were less common
after laser vaporisation (relative risk 0.54, 95%
confidence interval 0.32 to 0.90; P=0.02) than after
transurethral resection, with a consistent effect seen in
sixw6-w9 w13 w14 of nine studies reporting this outcome
(see supplementary figure 2 on bmj.com). In this
comparison, eight of the 13 (62%) strictures reported in
the laser vaporisation group and 11 of the 27 (41%)
strictures reported in the transurethral resection group
were bladder neck contractures (see supplementary
fig 2 on bmj.com).
Incontinence—Men undergoing laser vaporisation
had a higher risk of urinary incontinence (relative risk
2.24, 1.03 to 4.88; P=0.04) but the difference was seen
in only one trial,w15 with high rates in both groups, and
the type of incontinencewas not fully described. For all
the other interventions the occurrence of incontinence
did not differ compared with transurethral resection
(see supplementary fig 2 on bmj.com).
Urinary tract infection—No evidence was found of
differences in the occurrence of postoperative urinary
tract infection (see supplementary fig 2 on bmj.com).
Sexual dysfunction—Loss of ejaculation was less often
experienced by sexually active men undergoing laser
vaporisation (relative risk 0.22, 0.13 to 0.39; P<0.001)
or transurethral vaporisation (0.78, 0.64 to 0.95;
P<0.01) than transurethral resection. The risk of
erectile dysfunction was higher for sexually active
men undergoing laser vaporisation (8.89, 1.29 to
61.37), whereas the other interventions showed similar
rates to transurethral resection (table 2). This result
should be treated with caution as the confidence
interval was large and therefore clinically important
differences may have occurred between the two
groups.
Descriptors of care—Of the assessed interventions only
holmium laser enucleation showed a difference in
duration of surgery compared with transurethral
resection, taking on average 17 minutes longer (95%
confidence interval 13.45 to 20.47, P<0.001). Hospital
staywas shorter for all the interventions comparedwith
transurethral resection, generally by one day or less
(table 3). The need for a second procedure during
follow-up was more common after laser vaporisation
than after transurethral resection (9.3% v 5.4%; relative
risk 1.68, 95% confidence interval 0.97 to 2.63;
P=0.04). No evidence was found of differences in
reoperation rate between transurethral resection and
the other ablative procedures, but confidence intervals
were wide (table 3). Studies did not differentiate
between further procedures to correct complications
and those done for lack of efficacy.
DISCUSSION
In this systematic reviewweconsidereddata from3970
participants across 45 randomised controlled trials of
moderate to poor quality. We found no evidence of a
difference in outcomes for symptoms using any of the
newer technologies for endoscopic ablation of benign
enlargement of the prostate over transurethral resec-
tion at 12months, although therewas a trend favouring
holium laser enucleation and against laser vaporisa-
tion. Patterns of improvement in peak urine flow rate
were consistent with change in symptoms. Blood
transfusion rates were higher for transurethral resec-
tion than for the newer methods, with the exception of
bipolar transurethral resection. Men undergoing laser
or diathermy vaporisation were more likely to
experience urinary retention. Hospital stay was up to
one day shorter for the newer technologies.
The randomised controlled trials identified by this
review were not powered to detect differences in the
low rates of mortality and major morbidity associated
with transurethral resection of the prostate and
Holmium laser enucleation v TURP
  Gupta 2006w1
  Kuntz 2004w2
  Montorsi 2004w3
  Westenberg 2004w4
  Wilson 2006w5
Total (95% CI): 1.48 (0.56 to 2.40)
P=0.002, I2=9.3%
Laser vaporisation v TURP
  Keoghane 2000w8
  Shingleton 2002w11
Total (95% CI): -2.02 (-4.75 to 0.71)
P=0.15, I2=0%
Transurethral vaporesection v TURP
  Gupta 2006w1
  Helke 2001w17
Total (95% CI): 0.10 (-0.41 to 0.61)
P=0.70, I2=0%
Bipolar transurethral resection v TURP
  Nuhoglu 2006w24
  Seckiner 2006w25
  Tefekli 2005w23
Total (95% CI): 0.20 (-1.37 to 1.78)
P=0.80, I2=43%
Transurethral vaporisation v TURP
  Gupta 2006w1
   Hammadeh 2003w33
  Kaplan 1998w34
  Van Melick 2003w15
  Netto 1999w38
   Shokeir 1997w41
Total (95% CI): -0.03 (-1.19 to 1.14)
P=0.97, I2=65.9%
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61
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40
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50
79
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24
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96
50
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31
11
38
35
216
-10 -5 0 5 10
Peak urine flow rate (ml/s)
at 12 months
Favours
TURP
Favours
intervention
Random effects
Weighted mean
difference (95% CI)
No in
group
25.10 (1.06)
27.90 (9.90)
25.10 (7.20)
25.20 (11.90)
21.80 (10.50)
17.10 (13.20)
15.40 (5.90)
23.70 (1.58)
22.19 (12.30)
17.10 (2.70)
18.80 (6.90)
17.20 (3.90)
23.70 (1.58)
20.80 (7.70)
19.60 (4.90)
21.00 (8.00)
16.16 (2.48)
18.20 (3.00)
50
86
48
59
27
270
45
33
78
50
73
123
26
21
47
94
50
51
30
9
40
35
215 
23.70 (1.58)
27.70 (12.20)
24.70 (10.00)
20.40 (8.50)
18.40 (14.55)
21.20 (12.40)
16.70 (7.60)
23.60 (0.96)
22.12 (10.60)
17.90 (3.10)
15.70 (6.30)
16.90 (4.10)
23.60 (0.96)
22.50 (9.00)
16.90 (4.10)
23.00 (8.00)
15.43 (3.40)
20.10 (3.20)
Intervention
Mean (SD)
No in
group
TURP
Mean (SD)
Fig2 | Meta-analysesofpeakurineflowrate12monthsafterendoscopic techniques forablationof
benign enlargement of prostate. TURP=transurethral resection of prostate
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therefore we have used proxy variables such as
requirement for blood transfusion. Blood loss tends
to be less well tolerated by elderly men with cardiac or
renal comorbidity, which are common among men
selected for transurethral resection. The significant
reduction in the risk of transfusion seen with the newer
techniques reflects better haemostatic properties of the
energy sources used and is often perceived as their
main advantage over standard monopolar diathermy.
Although the relative risk reduction is considerable, the
absolute benefit is small and its clinical importance
could be challenged. The other key outcome was the
need for reoperation as a result of complications,
particularly stricture, or inadequate benefit for symp-
toms. The short term nature of the trials is a problem
though, with rates equivalent to transurethral resection
being documented at 12 months’ follow-up probably
reflecting treatment for complications rather than
inadequate response. In this regard vaporisation
procedures generally show slightly higher rates,
which may become of more concern as such problems
are likely to increase with longer observation. These
studies do not tell us about the long term need for
retreatment, which for transurethral resection is well
characterised at between 0.5% and 1% per year of
follow-up for up to 15 years. The risk of other
complications that may cause permanent disability,
such as incontinence and sexual dysfunction, do not
seem to be substantially altered in the short term using
the new technologies; however, confidence intervals
were wide and important differences cannot be ruled
out.
Another driver for change in countries with highly
developed healthcare services is reduction in hospital
stay. This is one area of achievement for the newer
endoscopic treatments for clinical benign enlargement
of the prostate, with an average saving of one bed day.
This is likely to be positively received by patients and
healthcaremanagers given the risks andcosts of stays in
hospital. It could be argued, however, that managed
care pathways are shortening hospital stay for all
procedures, including transurethral resection of pros-
tate, and inconsequence the cost saving forpatients and
healthcare providers may be small.6
Strengths and limitations of the review
We have used the best available methods to identify,
review, and meta-analyse data available to us. Several
limitations must be noted, however, when interpreting
the results of this review. Heterogeneity in results for
the primary outcome measure of reduction in symp-
tom score presented problems in deriving a validmeta-
analysis, whichwe overcameby using a randomeffects
model. Clinical reasons for this heterogeneity include
differences in baseline score for symptoms between
studies and failure to control for other variables that
may result in greater improvement in symptoms, such
as initial prostate volume and the presence of
urodynamic obstruction.
As with all secondary research it is possible to miss
data owing to non-publication or non-appearance on
the search strategy. A particular problem with the
present reviewwas that over half of the reports thatmet
the initial inclusion criteria were only in abstract form.
Thismade it impossible forus to assess all relevantdata,
and the exclusion of these studies prevented estimation
of publication bias. The reasons why so many trials
were reported only as abstracts were unclear and
ideally should be investigated because publication bias
in another setting accounted for up to 45% of an
observed association, which may change the direction
of effect.7
The moderate to poor methodological quality of the
studies, togetherwith the highnumber of comparisons,
diluted the opportunities for meta-analysis. The con-
fidence intervals around estimates of differences were
often wide and this may have resulted in a failure to
detect clinically important differences.8 9 The compar-
isons were against the standard of transurethral
resection of prostate and therefore this limited our
ability to assess how newer ablative treatments
performed against each other. Study inclusion criteria
such as prostate size also varied considerably between
the trials, which questions the generalisability of the
findings to everyday practice. This was exacerbated by
variation and evolution in operative technique and
treatment protocols between studies investigating the
same basic technology. These variations were of
particular concern for studies involving laser technol-
ogy where there was variation in wavelength and
power settings, together with site and duration of laser
application.
Table 3 | Descriptors of care after alternative approaches to endoscopic ablation for benign
enlargement of prostate
Outcome
No of trials in meta-
analysis (total reporting
outcome) Effect size (95% CI) P value
Holmium laser enucleation:
Duration of operation 5 (5) 16.96* (13.45 to 20.47) <0.001
Length of hospital stay 4 (4) −1.05* (−1.20 to −0.89) <0.001
Reoperation 4 (4) 0.68† (0.32 to 1.44) 0.31
Laser vaporisation:
Duration of operation 4 (9) 0.29* (−2.19 to 2.78) 0.82
Length of hospital stay 2 (9) −1.39* (−1.69 to −1.10) <0.001
Reoperation 9 (9) 1.68† (1.03 to 2.74) 0.004
Transurethral vaporesection
Duration of operation 2 (2) 1.06* (−8.70 to 10.83) 0.83
Length of hospital stay 1 (1) −0.41* (−0.54 to −0.28) <0.001
Reoperation 2 (2) 1.90† (0.80 to 4.52) 0.15
Bipolar transurethral resection:
Duration of operation 4 (5) −4.56* (−15.36 to 6.23) 0.41
Length of hospital stay 1 (2) −0.70* (−1.37 to −0.03) 0.04
Reoperation 3 (3) 1.46† (0.25 to 8.57) 0.67
Transurethral vaporisation:
Duration of operation 8 (14) −1.62* (−12.23 to 8.99) 0.76
Length of hospital stay 8 (11) −1.00* (−1.25 to −0.75) <0.001
Reoperation 7 (7) 1.04† (0.53 to 2.07) 0.90
*Weighted mean difference.
†Relative risk.
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  Helke 2001w17
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Fig 3 | Blood transfusion and urinary retention after endoscopic techniques for ablation of benign enlargement of prostate.
TURP=transurethral resection of prostate
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In the United Kingdom about 50% of endoscopic
prostatectomies are carried out for indications other
than lower urinary tract symptoms, predominantly
urinary retention. Exclusion of such patients from
randomised controlled trials considered in this review
makes it difficult to extrapolate the findings to these
circumstances, although the rationale for ablation
surgery of prostate is similar. It could be speculated
that the higher rate of voiding difficulties after
vaporisation procedures would tend to favour transur-
ethral resection, whereas the greater risk of bleeding
complications in men catheterised preoperatively
would favour the newer technologies. Ideally, men
undergoing surgery for retention should be included in
future trials.
Most of the included randomised controlled trials
were poorly reported, which may be associated with
low levels of methodological quality.8 10 Without
adequate reporting, the assessment of quality becomes
impossible,11 and the drive to ensure adherence to
standardised conduct and reporting guidelines for
randomised controlled trials has much to commend it
from the systematic reviewer’s point of view. Report-
ing of allocation concealmentwas unclear in 74%of the
included studies and14%usedan inadequate approach
for concealment of randomisation. This increases the
risk of selection bias by disrupting the assignment
sequence and may result in loss of the advantages of
randomisation, generating biased estimates of treat-
ment effects.11 12
Many studies failed to report point estimates and
measures of variability, which hinders calculation of
the precision of the overall pooled estimate and
calculation of weighted mean difference when a
standard deviation is required.13 It is possible that if
means and standard deviations were reported more
consistently, effect sizes would be different. This is
another reason why adherence to consolidated stan-
dards of reporting trials guidelines for reporting of
randomised controlled trials greatly aids the conduct of
robust meta-analyses.
The usefulness of individual trial data together with
systematic review is to some extent determined by the
current context of patient care, which often changes
before findings can be published. In the present case
some procedures such as transurethral vaporisation of
the prostate have been abandoneddespite a reasonable
evidence base for their efficacy. In contrast, techniques
using more recent technology such as bipolar transur-
ethral resection and potassium-titanyl-phosphate laser
vaporisation have now entered routine use without
adequate published evidence of safety and cost
effectiveness. In addition, the standard of transurethral
resection of prostate has not stood still, with the
improvements making the operation more uniform in
outcome and less morbid in terms of adverse effects.
Conclusions
On the basis of current evidence it is not possible to
reliably identify the most promising tissue ablative
intervention for benign enlargement of the prostate.
Transurethral resection of the prostate continues to be
effective although it is associated with potentially
significant morbidity. Of all the newer technologies
assessed in this study,holmium laser enucleation seems
to have the most promise. Nevertheless, the quality of
the available evidence is poor and therefore research
efforts in the management of benign prostatic enlarge-
ment should be concentrated on more efficient
performance of higher quality, more rigorous, rando-
mised controlled trials where outcomes and inter-
ventions are clearly defined and the timing of outcome
measurement is registered. It is also essential that the
reasons for reoperation are clearly stated, including
when this decision is largely driven by patient choice.
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